Industry Insights
Sep 05, 2026 · 1 min read · 27,942 views
BridgeBio Oncology slides as it tightens the scope of its KRAS program
N
Noah Patel
Editorial · Sep 05, 2026
BridgeBio Oncology's stock drops 24% as it narrows BBO-8520 to 2L+ NSCLC, trimming its broader KRAS pipeline plans
← Previous
Enveda raises its third megaround in as many years for I&I and weight maintenance drug candidates
Next →
Viking touts once-a-month maintenance data for its weight loss candidate
